{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.004","upperLimit":"0.30","value":"0.07"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Response was assessed using the criteria from International Workshop to Standardize Criteria for NHL (Cheson, 1999). OR=complete response(CR)+complete response/uncertain(CRu)+partial response(PR) CR: 1)Disappearance of clinical/radiographic evidence of disease (dz) and all dz-related B-symptoms; normalization of biochemical abnormalities attributed to NHL; 2)Lymph nodes and nodal masses regress to normal size; 3)Spleen, if enlarged before therapy, has decreased in size and is not palpable; 4)Complete resolution of lymphoma in bone marrow biopsy CRu: Meet criteria 1 and 3 above but with ≥1 of the followings. Residual dominant nodal mass \\>1.5 cm in greatest diameter that has decreased by \\>75%. Indeterminate bone marrow.\n\nPR: ≥50% decrease in SPD (sum of products of diameters) of 6 largest dominant nodes or nodal masses. No increase in size of liver or spleen. No unequivocal progression in nonmeasurable or nondominant sites. Splenic/hepatic nodules regress ≥50% in SPD. No new dz sites.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nsorafenib tosylate: Given orally","id":"OG000","title":"Treatment (Sorafenib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Assessed at the end of Cycle 2 and Cycle 6 (1 cycle = 28 days). Then every 3 months beginning Cycle 9 if patient is < 2 years from study entry, every 6 months if patient is 2-3 years from study entry, up to 3 years.","title":"Overall Response (OR) Rate","type":"PRIMARY","unitOfMeasure":"Proportion of participants"}